-
ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC DC
- 2:07-cv-03770
- D.N.J.
- Judge: Dennis M. Cavanaugh +2
- Filed: 08/09/2007
- Closed: 08/25/2010
- Latest Docket Entry: 06/24/2015
- PACER
- Docket updated daily
1
Plaintiff
11
Defendants
2
Accused
Products
1
Patent-in-Suit
1,113
Days in
Litigation
-
ELI LILLY AND COMPANY v. ACTAVIS ELIZABETH LLC DC
- 2:07-cv-03770
- D.N.J.
- Judge: Dennis M. Cavanaugh +2
- Filed: 08/09/2007
- Closed: 08/25/2010
- Latest Docket Entry: 06/24/2015
- PACER
- Docket updated daily
Cause of Action
Infringement
Market Sector
Biotech and Pharma
Court
Referred Judges
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
A method of treating attention-deficit/hyperactivity disorder comprising administering to a patient in need of such treatment an effective amount of tomoxetine.
|
Enforceable and Invalid (101)
Entry 686 |
2 |
A method of claim 1 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
3 |
A method of claim 1 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
4 |
A method of claim 1 wherein the combined type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
5 |
A method of claim 1 wherein the patient is an adult.
|
Enforceable and Invalid (101)
Entry 686 |
6 |
A method of claim 5 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
7 |
A method of claim 5 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
8 |
A method of claim 5 wherein the combined type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
9 |
A method of claim 1 wherein the patient is an adolescent.
|
Enforceable and Invalid (101)
Entry 686 |
10 |
A method of claim 9 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
11 |
A method of claim 9 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
12 |
A method of claim 9, wherein the combined type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
13 |
A method of claim 1 wherein the patient is a child.
|
Enforceable and Invalid (101)
Entry 686 |
14 |
A method of claim 13 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
15 |
A method of claim 13 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactive disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
16 |
A method of claim 13 wherein the combined type of attention-deficit/hyperactivity disorder is treated.
|
Enforceable and Invalid (101)
Entry 686 |
All Claims |
NA
|
Enforceable and Valid (102)
Entry 748 Entry 491 |
-
Infringement
Actavis Elizabeth LLC
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Apotex Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Aurobindo
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686
|
Mylan Pharmaceuticals Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Sandoz Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Sun Pharmaceuticals
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Synthon Laboratories Incorporated
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686
|
Teva Pharmaceutical
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgAtomoxetine capsulesGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686Entry 491 Entry 332 Entry 506 |
Zydus Pharmaceuticals (USA) Inc.
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
18 mg25 mg40 mg60 mg80 mgGeneric Atomoxetine Hydrochloride Capsules Eq 10 mg | US 5,658,590 A |
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
|
Infringement
Entry 686
|